For research use only. Not for therapeutic Use.
SB649868(CAT: I009348), also known as GSK-649868 is an orexin receptor antagonist that has been studied for the treatment of insomnia and sleep disorders. It acts by blocking the activity of the orexin neuropeptides, which play a role in the regulation of wakefulness and sleep. Clinical studies have shown that SB649868 can promote and maintain sleep in individuals with primary insomnia. It has demonstrated potential as an effective and well-tolerated treatment option for patients with sleep disorders.
| Catalog Number | I009348 |
| CAS Number | 380899-24-1 |
| Synonyms | GSK-649868; GSK-649868; GSK649868; SB649868; SB-649868; SB 649868.;(S)-N-((1-(5-(4-fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide |
| Molecular Formula | C26H24FN3O3S |
| Purity | ≥95% |
| Target | orexin receptor antagonist |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| SMILES | O=C(C1=C2C=COC2=CC=C1)NC[C@H]3N(C(C4=C(C5=CC=C(F)C=C5)SC(C)=N4)=O)CCCC3 |
| Reference | </br> 1: Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol. 2014 Nov;7(6):711-30. doi: 10.1586/17512433.2014.966813. Review. PubMed PMID: 25318834.</br> 2: Patel AX, Miller SR, Nathan PJ, Kanakaraj P, Napolitano A, Lawrence P, Koch A, Bullmore ET. Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans. Psychopharmacology (Berl). 2014 Oct;231(19):3817-28. doi: 10.1007/s00213-014-3520-7. PubMed PMID: 24770625; PubMed Central PMCID: PMC4159598.</br> 3:Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Neuropeptides. 2013 Dec;47(6):477-88. doi: 10.1016/j.npep.2013.10.009. Review. PubMed PMID: 24215799. |
